TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clopidogrel-naïve stable angina pectoris (CCS I-III)~* Coronary angiography that reveals significant DE NOVO coronary stenosis (diameter stenosis greater than 50% in two independent projections) feasible for ad hoc stent implantation~Exclusion Criteria:~* Acute coronary syndrome (STEMI, NSTEMI or unstable angina)~* Administration of clopidogrel/ticlopidine/coumarin in the past 6 weeks~* Contraindication to antiplatelet therapy~* Significant LM stenosis~* PCI due to instent restenosis~* Lesion located in bypass grafts~* Stroke in past one year~* Reduced life expectancy

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
- 2 (Type: EXPERIMENTAL): Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
- 3 (Type: ACTIVE_COMPARATOR): Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline liver biopsy with macrovesicular fatty degeneration with inflammation (lobular or portal), with or without Mallory bodies, hepatocyte damage, and/or fibrosis diagnostic of NAFLD~* Convincing evidence of negligible alcohol consumption (\< 20 grams of ethanol per day) obtained from a detailed history, confirmed by at least one close relative~* If hyperlipidemia or diabetes, stable drug regimen required for the 6 months prior to and during the study~* Willingness to maintain stable weight and normal exercise program for the duration of the study, if randomized to vitamin E or betaine~Exclusion Criteria:~* Liver disease of other etiology diagnosed as per routine medical investigation (e.g., chronic viral hepatitis, auto-immune chronic hepatitis, primary biliary cirrhosis or genetic liver disease such as Wilson's disease, hemochromatosis, alpha-1 antitrypsin deficiency, or biliary obstruction)~* Complications of liver disease such as recurrent variceal bleeding, resistant ascites, spontaneous portosystemic encephalopathy, or bacterial peritonitis~* Concurrent medical illness contra-indicating a liver biopsy, history of unexplained bleeding, hemophilia or abnormal coagulation results as per routine laboratory work-up or other reason judged by the hepatologist to contra-indicate a percutaneous liver biopsy~* Medications known to precipitate steatohepatitis (corticosteroids, high dose estrogens, methotrexate, amiodarone, calcium channel blockers, spironolactone, sulfasalazine, naproxen, oxacillin or ampinovire) in the 6 months prior to entry~* Antioxidant vitamin supplementation, ursodeoxycholic acid, or any other experimental drug 6 months prior to study entry~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin E (Type: EXPERIMENTAL): alpha-tocoperol, capsules, 2 per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ARDS according to Berlin's definition~* PCR confirmed COVID-19~* Length of mechanical ventilation less or equal to 72 hours~Exclusion Criteria:~* Pregnancy or breast-feeding women~* Terminal illness with very poor prognosis according to the investigator judgement~* Therapeutic limitation~* Known immunocompromised condition~* Chronic use of systemic corticosteroids~* Participation in another randomized crinical trial~* More than 5 days of treatment of low dose dexamethasone for COVID-19~* Abscence of informed consent~* Active participation in other randomized clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose Dexamethasone (Type: EXPERIMENTAL): Intravenous Dexamethasone 16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10
- Usual care - low dose Dexamethasone (Type: NO_INTERVENTION): Intravenous Dexamethasone 6 mg qd for 10 days based on RECOVERY trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Women or men greater than or equal to 18 years of age~* Advanced cutaneous T-cell lymphoma, stage IB or higher including Sezary Syndrome with progressive, persistent, or recurrent disease~* Failure of at least one systemic therapy, not including Bexarotene (Targretin)~* Eastern Cooperative Oncology Group (ECOG) status less than or equal to 2 (measurement to determine your ability to perform daily activities)~Exclusion Criteria:~* Patient has had investigational treatment in the preceding 30 days~* Active hepatitis B or C, history of HIV~* Prior treatment with any HDAC inhibitor~* Patients must be disease free from prior malignancies for greater than 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter\[2\] daily x 7 days per week
- Cohort 2 (Type: EXPERIMENTAL): Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter\[2\] daily x 7 days per week
- Cohort 2a (Type: EXPERIMENTAL): Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter\[2\] daily x 7 days per week
- Cohort 2b (Type: EXPERIMENTAL): Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter\[2\] daily x 7 days per week
- Cohort 6 (Type: EXPERIMENTAL): Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
- Cohort 7 (Type: EXPERIMENTAL): Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week \[150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Oxygen Therapy for Diabetic Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Able to give informed consent, willing and able to visit the hospital and CWC for regular treatment and follow-up visits.~* Diabetic~* -Chronic wound OR Foot Ulcer:~* Ulcer present by history ≥ 4 weeks at time of enrollment~* Compliant with standard wound care regimen~* IF foot wound, Wagner grade 1 and 2, OR Wagner grade 3~* Ulcer size: 0.6 cm2 to 20 cm2 and has not decreased in size by more than 30% in previous 2 weeks of the enrollment visit~* Adequate circulatory status, as evidenced by any of the following:~* Ankle Brachial Index (ABI) ≥0.7 - ≥ 1.20~* If ABI non-compressible (ABI \>1.2), then toe brachial Index (TBI)\>0.5~* SPP \> 30mmHg~* TcOM \> 30mmHg~* At least 4 weeks since revascularization procedure, if one has been performed~* Able to complete Topical Oxygen Therapy 4 day/week for 16 weeks (must be able to remove existing wound dressing and apply TO2 Boot/treatment, and then re-dress wound)~Exclusion Criteria:~* Ulcer in area of radiation treatment.~* Active malignancy at site of ulcer~* Current treatment with wound VAC or weekly compression dressing~* Untreated infection at site of ulcer (i.e. cellulitis or osteomyelitis)~* If acute osteomyelitis has been diagnosed, patient may be enrolled only after the infection has been controlled. Including:~  1. Debridement of infected bone if necessary~ 2. Patient has received at least 2 weeks of appropriate antibiotics~* ABI \< 0.7 or \> 1.2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care with Topical Oxygen Treatment (Type: EXPERIMENTAL): patients who have a chronic wound, will receive their receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities).
- Standard of Care only (Type: NO_INTERVENTION): patients that have a chronic wound will receive only their standard of care treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of uncomplicated gastroschisis~* Gestational age \>33 weeks at time of delivery~* Weight \>1900g at time of delivery~* Transfer of patient to Riley Hospital for Children prior to any abdominal surgery~Exclusion Criteria:~* Neurological Congenital malformations and/or those known to impair intestinal motility~* Additional congenital gastrointestinal abnormalities requiring surgical intervention~* Congenital Cyanotic heart disease~* Surgical Closure of abdominal wall defect with prosthetic material (e.g. prosthetic or bio-prosthetic mesh)

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 1 Year
- Healthy Volunteers: t

Study Arms:
- Glycerin Suppository Group (Type: EXPERIMENTAL): None
- Non-suppository Group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient suffering from Crohn's disease, ulcerative colitis, unclassifiable colitis or pouchitis.~* Disease needing to be treated by corticoids and/or immunosuppressive drugs.~* Infection by cytomegalovirus.~* New attack during the three previous months.~Exclusion Criteria:~* Serious or complicated attack, needing to be operated.~* Patient suffering from a psychiatric disease or is uncooperative.~* Patient suffering from another serious disease.~* Patient already participating in another clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: INSORB Versus Subcuticular Sutures at Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cesarean section via transverse skin incision informed consent~Exclusion Criteria:~* vertical skin incision

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Sutures (Type: ACTIVE_COMPARATOR): None
- Insorb Staples (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Indications for cardiac surgery (CABG, valve surgery or CABG and valve surgery, Able to provide informed consent.~Exclusion Criteria:~* Documented atrial fibrillation within the previous 3 months~* Ongoing therapy with suppressive antiarrhythmic drugs~* Patient currently on digoxin~* Emergent surgery~* Patient receiving hemodialysis~* Concomitant use of ketoconazole, diltiazem, verapamil~* Known tolerance or hypersensitivity to ranolazine~* Pregnant individuals~* MAZE procedure (is a surgical ablation to treat atrial fibrillation) performed during concurrent cardiac surgery

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CABG surgery with Ranolazine (Type: ACTIVE_COMPARATOR): Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
- CABG surgery with placebo (Type: PLACEBO_COMPARATOR): Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
- Heart Valve surgery with Ranolazine (Type: ACTIVE_COMPARATOR): Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
- Heart Valve surgery with placebo (Type: PLACEBO_COMPARATOR): Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with \>= 70% carotid stenosis (unilateral or bilateral) who are scheduled to undergo elective carotid endarterectomy~* Age \>= 18 years~* Agreement of the operating surgeon for patient to participate~Exclusion Criteria:~* Surgery scheduled \< 14 days after randomization~* Pregnancy~* ALT, GGT \> 3x upper limit of normal (ULN)~* Creatinine \> 3.5 mg/dL~* Prior intolerance to statins~* Reluctance to add or change dosage of statin therapy during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: Fasudil hydrochloride (Type: EXPERIMENTAL): Fasudil hydrochloride 40 mg three times a day X 14 days
- Drug: Placebo oral tablet (Type: PLACEBO_COMPARATOR): Placebo 1 tablet three times daily x 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.~* Male or female aged 18-65 years (both inclusive)~* T2DM diagnosis~Exclusion Criteria:~* Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics~* Use of GLP-1 mimetics or DPP-IV inhibitors~* Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): The highest injected once daily dose will be 1.8 mg s.c. for liraglutide.
- Lixisenatide (Type: EXPERIMENTAL): The highest injected once daily dose will be 20µg s.c. for lixisenatide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 25-75 years~* at least one histologically confirmed adenoma endoscopically removed from the large bowel resulting in a polyp-free colon-rectum (clean colon).~Exclusion Criteria:~* polypectomy performed more than 6 months before enrolment in the trial~* history of Familial Adenomatous Polyposis~* inflammatory bowel disease~* adenoma with invasive carcinoma~* ten or more adenomas~* large sessile adenoma (3 cm or more~* colorectal resection~* invasive cancer at any site~* life-threatening and/or chronic heart, liver or kidney diseases~* current use of vitamin or calcium supplements~* mental disability

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- antioxidants (Type: EXPERIMENTAL): tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
- Sugar pill (Type: PLACEBO_COMPARATOR): placebo had an identical appearance as intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Leech Therapy for Postherpetic Neuralgia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 to 85 years of age~* \>6 months thoracal postherpetic neuralgia~* informed consent~Exclusion Criteria:~* if leech therapy is contraindicated~* physical and mental disability to participate in the study examinations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Leech therapy (Type: None): Patients receiving leech therapy in the outpatient clinic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues